246 related articles for article (PubMed ID: 25545020)
1. Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term.
Macías J; Mancebo M; Márquez M; Merino D; Téllez F; Rivero A; von Wichmann MA; López-Cortés LF; Merchante N; Santos J; Raffo M; Pérez-Pérez M; Camacho Á; Iribarren JA; Pineda JA
Hepatology; 2015 May; 61(5):1503-11. PubMed ID: 25545020
[TBL] [Abstract][Full Text] [Related]
2. Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.
Macías J; Márquez M; Téllez F; Merino D; Jiménez-Aguilar P; López-Cortés LF; Ortega E; von Wichmann MA; Rivero A; Mancebo M; Santos J; Pérez-Pérez M; Suárez-Lozano I; Romero-Palacios A; Torres-Cornejo A; Pineda JA
Clin Infect Dis; 2013 Nov; 57(10):1401-8. PubMed ID: 23946224
[TBL] [Abstract][Full Text] [Related]
3. Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients.
Macías J; Camacho A; Von Wichmann MA; López-Cortés LF; Ortega E; Tural C; Ríos MJ; Merino D; Téllez F; Márquez M; Mancebo M; Pineda JA
AIDS; 2013 Oct; 27(16):2541-9. PubMed ID: 23736148
[TBL] [Abstract][Full Text] [Related]
4. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
5. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
6. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Merchante N; Rivero-Juárez A; Téllez F; Merino D; José Ríos-Villegas M; Márquez-Solero M; Omar M; Macías J; Camacho A; Pérez-Pérez M; Gómez-Mateos J; Rivero A; Antonio Pineda J;
Hepatology; 2012 Jul; 56(1):228-38. PubMed ID: 22278746
[TBL] [Abstract][Full Text] [Related]
7. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography.
Pérez-Latorre L; Sánchez-Conde M; Rincón D; Miralles P; Aldámiz-Echevarría T; Carrero A; Tejerina F; Díez C; Bellón JM; Bañares R; Berenguer J
Clin Infect Dis; 2014 Mar; 58(5):713-8. PubMed ID: 24265358
[TBL] [Abstract][Full Text] [Related]
8. Liver Fibrosis Evaluation Using Real-time Shear Wave Elastography in Hepatitis C-Monoinfected and Human Immunodeficiency Virus/Hepatitis C-Coinfected Patients.
Verlinden W; Bourgeois S; Gigase P; Thienpont C; Vonghia L; Vanwolleghem T; Michielsen P; Francque S
J Ultrasound Med; 2016 Jun; 35(6):1299-308. PubMed ID: 27151906
[TBL] [Abstract][Full Text] [Related]
9. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
10. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography.
Masuzaki R; Tateishi R; Yoshida H; Goto E; Sato T; Ohki T; Imamura J; Goto T; Kanai F; Kato N; Ikeda H; Shiina S; Kawabe T; Omata M
Hepatology; 2009 Jun; 49(6):1954-61. PubMed ID: 19434742
[TBL] [Abstract][Full Text] [Related]
11. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
Barreiro P; Martín-Carbonero L; Núñez M; Rivas P; Morente A; Simarro N; Labarga P; González-Lahoz J; Soriano V
Clin Infect Dis; 2006 Apr; 42(7):1032-9. PubMed ID: 16511772
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients.
Pineda JA; González J; Ortega E; Tural C; Macías J; Griffa L; Burgos A;
J Viral Hepat; 2010 Oct; 17(10):714-9. PubMed ID: 20002560
[TBL] [Abstract][Full Text] [Related]
13. Course of liver fibrosis in HIV-hepatitis C virus-coinfected patients depending on the response to hepatitis C therapy.
Cartón JA; Collazos J; de la Fuente B; Asensi V
AIDS Res Hum Retroviruses; 2013 Feb; 29(2):215-22. PubMed ID: 22734850
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients.
Fernández-Montero JV; Vispo E; Barreiro P; Sierra-Enguita R; de Mendoza C; Labarga P; Soriano V
Clin Infect Dis; 2014 Jun; 58(11):1549-53. PubMed ID: 24633686
[TBL] [Abstract][Full Text] [Related]
15. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.
Pineda JA; Aguilar-Guisado M; Rivero A; Girón-González JA; Ruiz-Morales J; Merino D; Ríos-Villegas MJ; Macías J; López-Cortés LF; Camacho A; Merchante N; Del Valle J;
Clin Infect Dis; 2009 Oct; 49(8):1274-82. PubMed ID: 19772387
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.
Berenguer J; Zamora FX; Aldámiz-Echevarría T; Von Wichmann MA; Crespo M; López-Aldeguer J; Carrero A; Montes M; Quereda C; Téllez MJ; Galindo MJ; Sanz J; Santos I; Guardiola JM; Barros C; Ortega E; Pulido F; Rubio R; Mallolas J; Tural C; Jusdado JJ; Pérez G; Díez C; Álvarez-Pellicer J; Esteban H; Bellón JM; González-García J;
Clin Infect Dis; 2015 Mar; 60(6):950-8. PubMed ID: 25422386
[TBL] [Abstract][Full Text] [Related]
17. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy.
Labarga P; Fernandez-Montero JV; Barreiro P; Pinilla J; Vispo E; de Mendoza C; Plaza Z; Soriano V
J Viral Hepat; 2014 Jul; 21(7):475-9. PubMed ID: 24750394
[TBL] [Abstract][Full Text] [Related]
18. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
Pembroke T; Deschenes M; Lebouché B; Benmassaoud A; Sewitch M; Ghali P; Wong P; Halme A; Vuille-Lessard E; Pexos C; Klein MB; Sebastiani G
J Hepatol; 2017 Oct; 67(4):801-808. PubMed ID: 28527666
[TBL] [Abstract][Full Text] [Related]
19. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
[TBL] [Abstract][Full Text] [Related]
20. Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis.
García-García JA; Romero-Gómez M; Girón-González JA; Rivera-Irigoin R; Torre-Cisneros J; Montero JL; González-Serrano M; Andrade RJ; Aguilar-Guisado M; Grilo I; Martín-Vivaldi J; Salmerón J; Caballero-Granado FJ; Macías J; Vergara-López S; Pineda JA; ;
AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1236-41. PubMed ID: 17209765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
